304360 — S Biomedics Co Balance Sheet
0.000.00%
- KR₩421bn
- KR₩429bn
- KR₩17bn
Annual balance sheet for S Biomedics Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | — | — | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 12,839 | 7,073 | 10,591 | 23,270 | 14,522 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 469 | 1,540 | 2,228 | 2,100 | 1,872 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 14,342 | 11,201 | 15,700 | 29,272 | 19,831 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3,051 | 2,765 | 4,962 | 4,475 | 19,004 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 17,796 | 24,358 | 31,947 | 44,601 | 41,219 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4,175 | 11,831 | 7,731 | 11,770 | 12,319 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 15,285 | 28,136 | 25,015 | 32,736 | 32,542 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| ESOP Debt Guarantee | |||||
| Other Equity | |||||
| Total Equity | 2,510 | -3,779 | 6,932 | 11,865 | 8,677 |
| Total Liabilities & Shareholders' Equity | 17,796 | 24,358 | 31,947 | 44,601 | 41,219 |
| Total Common Shares Outstanding |